Zobrazeno 1 - 10
of 25
pro vyhledávání: '"R Barastegui"'
Autor:
A Arenas, M J Moreta, I Ordás, A Fernández-Clotet, B Caballol, M Gallego, A Vara, R Barastegui, A Giner, C Prieto, M C Masamunt, E Ricart
Publikováno v:
Journal of Crohn's and Colitis. 17:i829-i831
Background Combination therapy with an immunomodulator (IMM) and an anti-TNF agent (specifically infliximab) is recommended in Crohn’s disease (CD) and ulcerative colitis (UC) patients to improve efficacy and reduce anti-TNF immunogenicity. Combo t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bff4ed1d892d02429f36bfe4f39fb33
https://doi.org/10.1093/ecco-jcc/jjac190.0827
https://doi.org/10.1093/ecco-jcc/jjac190.0827
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
B Caballol Oliva, A Fernàndez-Clotet, J Panés, M C Masamunt, M Gallego, R Barastegui, A Vara, À Giner, E Ricart, I Ordás
Publikováno v:
Journal of Crohn's and Colitis. 17:i618-i618
Background A new formulation of biosimilar infliximab (IFX) has recently been approved for subcutaneous administration (SC) that may offer pharmacokinetic advantages resulting in higher drug exposure. Our purpose was to evaluate the efficacy, safety,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb9a9a630d94d259925f448ebf4d7470
https://doi.org/10.1093/ecco-jcc/jjac190.0618
https://doi.org/10.1093/ecco-jcc/jjac190.0618
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Azucena Salas, Alejandro Vara, A. Giner, R. Barastegui, Marta Gallego, Elena Ricart, Ingrid Ordás, Ignacio Alfaro, Julián Panés, Alicia López-García, Maria Carme Masamunt, Jesús Castro, Núria Planell
Publikováno v:
World Journal of Gastroenterology
BACKGROUND Identifying predictors of therapeutic response is the cornerstone of personalized medicine. AIM To identify predictors of long-term mucosal healing (MH) in patients with Crohn’s disease (CD) treated with tumor necrosis factor α (TNF-α)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8097baeefd6230a070e84a3c80a7fb2
https://doi.org/10.3748/wjg.v25.i14.1764
https://doi.org/10.3748/wjg.v25.i14.1764
Publikováno v:
Enfermedad Inflamatoria Intestinal al Día. 16:70-76
Resumen La enfermedad de Crohn afecta a una parte de la poblacion joven y tiene un fuerte impacto en la calidad de vida. Su etiologia es desconocida y los farmacos existentes no son curativos. Ademas, una proporcion significativa de pacientes present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d3ca00325016b43d5f9416422c620d5
https://doi.org/10.1016/j.eii.2016.09.007
https://doi.org/10.1016/j.eii.2016.09.007
Autor:
Julián Panés, Elena Ricart, R. Barastegui, A. Giner, Jesús Castro-Poceiro, Maica Masamunt, Marta Gallego, Agnès Fernández-Clotet, Anna Ramírez-Morros, Sonia Rodríguez, Ignacio Alfaro, Jordi Rimola, Ingrid Ordás
Publikováno v:
Gastroenterology. 157(2)
The magnetic resonance index of activity (MARIA) for Crohn's disease (CD) is used to assess the activity of luminal CD. However, it has a number of practical limitations. We aimed to develop and validate a simplified MARIA to more easily and quickly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::895e5bd65ff93cc45a397de27058d929
https://pubmed.ncbi.nlm.nih.gov/31704303
https://pubmed.ncbi.nlm.nih.gov/31704303
Autor:
A Andonova, R Barastegui, E. Schiavoni, A Heil, W Czuber-Dochan, Christine Norton, S Jäghult, L Turchini, C Fernández-Fernández, E Navarro, A Giner-Agudo, F Murciano, A der Heer-Damen, Antonello Cocchieri, S Radice, Maurizio Zega, Micol Artom, M Chalabreysee, D Napolitano, R Barkan, A Rivera, Marta Gallego, K Pihl Lesnovska, I Goren, V Cluzeau, A Vara-Hernández, L Shpoker, Lars-Petter Jelsness-Jørgensen, M Pencova, L Moortgat
Publikováno v:
Journal of Crohn's and Colitis. 12:S566-S567
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc23c93cd362ba5253418dc301b62a5f
https://doi.org/10.1093/ecco-jcc/jjx180.1013
https://doi.org/10.1093/ecco-jcc/jjx180.1013
Autor:
Joan Cid, Vicent Ribas, Faust Feu, Alicia López-García, Ignacio Alfaro, Azucena Salas, Aranzazu Jauregui-Amezaga, Julián Panés, Maria Carme Masamunt, Gonzalo Gutierrez, Dolors Comas, Pedro Marín, Miguel Lozano, María Suárez-Lledó, A. Giner, Carmen Martinez, Francesc Fernández-Avilés, J. Ignasi Elizalde, Ingrid Ordás, Alvaro Urbano, Enric Carreras, Montserrat Rovira, Elena Ricart, Laura Rosiñol, R. Barastegui, Marta Gallego
Publikováno v:
Journal of Crohn'scolitis. 11(10)
Background Haematopoietic stem cell transplantation [HSCT] is considered a therapeutic option for patients with severe Crohn's disease [CD] unresponsive to currently available therapies. Methods Autologous HSCT was considered for CD patients with act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2718730797a01bc9bd6800d3822c8d03
https://pubmed.ncbi.nlm.nih.gov/28419282
https://pubmed.ncbi.nlm.nih.gov/28419282